Introduction
It is challenging to obtain a reliable bleeding history in children who are referred for a suspected inherited bleeding disorder. Bleeding symptoms may be subtle as children face fewer hemostatic challenges compared to adults. In order to standardize bleeding histories, questionnaires have been developed, called bleeding assessment tools (BAT). Although it has been shown that high bleeding scores are associated with the presence of a mucocutaneous bleeding disorder, these BATs lack sensitivity, efficiency and flexibility in the pediatric setting. We developed a new BAT (iCHEC BAT) that improved on these characteristics. We aim to evaluate the diagnostic accuracy of the iCHEC BAT as a screening tool for children who are suspected for having a bleeding disorder.
Methods and analysis
This is a prospective cohort study. Children (age 0-18 years) suspected for a bleeding disorder who present at tertiary hematology clinics, or their parents/guardians, will be asked to complete the iCHEC BAT. Sensitivity was increasedby inclusion of pediatric-specific bleeding symptoms and novel qualitative questions per bleeding symptom. Efficiency was improved by developing a self-administered (online) version of the questionnaire. Flexibility for changes in the bleeding phenotype of developing children was improved by including questions about that that define when the bleeding symptoms occurred in the past. The diagnostic accuracy of the specific bleeding items will be evaluated by receiver operator characteristic curves, using classification based on the results form laboratory assessment as the reference standard. Furthermore, analysis of the discriminative power of individual bleeding symptoms will be assessed.
Ethics and dissemination
The study has been approved by the medical ethics committees of all participating centers in the Netherlands, Canada and the United Kingdom. All pediatric subjects and/or their parents/guardians will provide written informed consent. Study results will be submitted for publication in peer-reviewed journals. 
STRENGTHS AND LIMITATIONS OF THE STUDY
• Strength: A self-administered (online) version of the iCHEC BAT is available; patients and/or their parents/guardians can fill in the questionnaire prior to their visit to the doctor, which makes the assessment of the bleeding history more efficient.
• Strength: The iCHEC BAT is designed to pick up subtle cues in the bleeding history of a child, thereby improving sensitivity.
• Limitation: The results of this study are not generalizable to primary and secondary care due to a different spectrum of prevalence of inherited bleeding disorders compared to tertiary hematology centers; additional studies will be required to determine diagnostic performance of the iCHEC BAT in these settings. 
INTRODUCTION
The diagnosis of an inherited bleeding disorder is based on the results derived from a patient's bleeding history from birth, a family history and laboratory test results. Patients with mild bleeding disorders usually exhibit mild to moderate bleeding tendencies and are therefore difficult to distinguish from normal subjects. Especially in children it is difficult for the doctor to obtain a reliable bleeding history, as bleeding symptoms can be subtle, children face fewer hemostatic challenges compared to adults and, for example, bruises in toddlers may be caused by normal activity. Also, some of the classic bleeding symptoms which are often present in adults with a bleeding disorder, such as menorrhagia and post-surgical bleeding, are usually not yet present in young children. Nevertheless, these children may have other bleeding symptoms that are caused by a bleeding disorder and require treatment.
In order to standardize bleeding histories, questionnaires have been developed, so called bleeding assessment tools (BAT) 1 . Typically, a BAT consists of questions about various bleeding symptoms, such as epistaxis, bleeding from minor wounds and bleeding after surgical procedures. After completion of the questionnaire, a summative bleeding score can be calculated. In 2009, the Pediatric Bleeding Questionnaire (PBQ) was developed and validated for the screening of a child for von Willebrand disease (vWD) 2 . Then, in 2010, the
International Society on Thrombosis and Haemostasis/Scientific and Standardization
Committee (ISTH/SSC) developed the ISTH-BAT 3 that is recommended for use in hematology clinics. Both the PBQ and the ISTH-BAT contain categories with questions for various bleeding symptoms, 12 and 13 different bleeding symptoms respectively, and one category that includes pediatric-specific bleeding symptoms (Table 1) .
It has been shown that high bleeding scores are associated with the presence of an inherited bleeding disorder 4 . However, the PBQ and ISTH-BAT are not sensitive to pick up subtle cues in the bleeding history of a child and this may lead to underreporting of bleeding symptoms. Also, the PBQ and ISTH-BAT are inflexible with respect to changes in the bleeding phenotype of rapidly developing children. Finally, a self-administered BAT would help to optimize the efficiency of bleeding history assessment. Thus, optimization of this screening tool is necessary.
Therefore, we have developed a novel BAT: the iCHEC BAT. For construction of the iCHEC BAT, the PBQ and ISTH-BAT were used as templates. From a thorough literature review and consultation with experts, we have identified additional pediatric-specific bleeding symptoms and qualitative questions per bleeding symptom. These items and questions were added to the iCHEC BAT to increase its sensitivity for detection of subtle cues in the bleeding history. The PBQ and ISTH-BAT calculate a bleeding score based on information about the medical treatment of the most severe bleeding episode for specific bleeding symptoms. With the use of such a scoring system, the majority of information about the bleeding symptoms is is not used for diagnostic purposes. In contrast to the scoring systems of the PBQ and ISTH-BAT, the iCHEC BAT scoring system will use all the information that has been collected from the completed questionnaire for calculating a bleeding score. For example, information about the frequency and duration of nosebleeds for the bleeding item 'epistaxis' will be scored in the iCHEC BAT, whereas the PBQ and ISTH-BAT do not score this information since they only include information about the treatment of the most severe epistaxis episode for calculating the bleeding score. We have improved the flexibility of the iCHEC BAT by addressing time dependent occurrence of bleeding symptoms, which makes it sensitive to changes in the bleeding phenotype of a child. To improve efficiency, we have developed a self-administered version of the iCHEC BAT, using careful wording and lay terms that are easy to understand 5 . The iCHEC BAT was first designed in English language and has been translated forward into Dutch and backward to English to uncover mistakes in the Dutch translation. No major differences occurred between the original version and the backward translated version. From the age of 12 years, children are allowed to fill in the questionnaire by themselves or with the help of their parents/guardians. Who completed the iCHEC BAT will be recorded. Eventually, this study will compare the diagnostic performance of the iCHEC BAT with the PBQ and ISTH-BAT, which is possible because the iCHEC questionnaire includes the essential questions that are required for calculating the PBQ and ISTH-BAT bleeding scores.
The main goal of this study is to evaluate the diagnostic accuracy of the iCHEC BAT, using results from laboratory screening tests as reference (gold standard). 
METHODS

Study design
This is a prospective cohort study. The cohort will include 200 children who are suspected for having an inherited bleeding disorder at tertiary hematology clinics in the Netherlands, Canada and the United Kingdom (UK). Data collection will continue until the required number of 200 patient inclusions has been reached and is expected to take approximately one year.
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet the following criteria:
• Aged 0-18 years, and
• Patients presenting with: (1) the history, signs and symptoms of bleeding, and/or (2) referred for evaluation of abnormal laboratory results (of blood coagulation parameters), and/or (3) a positive family history of an inherited bleeding disorder
Exclusion criteria
A subject who meets any of the following criteria will be excluded from participation in this study:
• Patients with a previous diagnosis of an inherited bleeding disorder
• Patients with a known, acquired cause of bleeding, for example renal or liver disease or use of medication that is known to cause an increased bleeding tendency
• Patients and/or caregivers who are not capable to fill in the questionnaire, for example due to illiteracy
Sample size calculation
The prevalence of an inherited bleeding disorder in children presenting with bleeding symptoms at a tertiary clinic is approximately 20-25% 6, 7, 8 . Assuming a sensitivity of 90% and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   7 specificity of 70%, a sample size of 200 children, of which about 45 will be affected, will yield 95% confidence intervals (CI) of 76-96% and 64-78% for sensitivity and specificity, respectively, which we consider sufficiently narrow.
Recruitment and consent
Recruitment and consent procedures of patients at participating centers in the Netherlands will be as follows: after referral and scheduling the appointment for evaluation of bleeding symptoms at the participating tertiary hematology clinic, subjects will be informed by email or by letter about this study. The secured link to the online version of the iCHEC BAT will be sent by email to the study participants. Patients and/or caregivers will fill in the questionnaire prior to the doctor's appointment. Informed consent will be signed by one of investigators or the treating physician when the patient visits the hospital with both parents/guardians of the patient and the the patient, when 12 years or older.
Recruitment and consent procedures of patients at participating centers outside the Netherlands will proceed according to local standard procedures.
Outcomes
The main study outcome is the diagnostic accuracy of the iCHEC BAT, as reflected by the Area Under the Curve (AUC) of a Receiver Operating Characterics (ROC) curve using results from the laboratory assessment as the reference standard. The secondary outcomes are the influence of age, sex and type of bleeding disorder on the total cumulative bleeding score and the score of individual bleeding items.
Data collection
Patient characteristics
The following patient data will be collected: month and year of birth to calculate age; body weight and height to calculate BMI; family history; medical history; and use of medication.
iCHEC BAT
An online version of the iCHEC BAT is available for patients included in the Netherlands.
Patients and/or their parents/guardians fill in the questionnaire at a computer before they visit the doctor in the hospital. For patients included outside the Netherlands, a paper version of the questionnaire is available. These patients and/or parents/guardians fill in the questionnaire in the waiting room before they visit the doctor. The questions that are necessary to calculate the PBQ and ISTH-BAT bleeding scores are incorporated in the iCHEC BAT. Bleeding scores will be calculated, including the total summative bleeding score, scores per bleeding item and scores of individual questions per bleeding item. 
Diagnostic work-up
Participants will undergo a uniform diagnostic laboratory work-up for hemorrhagic disorders which is similar to the standard work-up that is performed as part of routine care. Parameters include:
• ABO blood group
• Complete blood count, including Mean Platelet Volume (MPV)
• Activated Partial Thromboplastin Time (aPTT)
• Prothrombin Time (PT)
• Fibrinogen
• Thrombin time
• Factor VIII Activity (FVIII:C), FIX:C, von Willebrand Factor Antigen level (vWF:Ag) and von Willebrand Factor Activity (vWF:Act)
• FVII:C, FXI:C, FXIII:C
• Platelet aggregation tests (when indicated)
Additional laboratory tests
In participating centers in the Netherlands, we will collect extra blood for additional platelet tests in a subgroup of patients. This subgroup includes subjects with a high iCHEC bleeding score, who were not diagnosed with a bleeding disorder on the basis of routine diagnostic laboratory tests. In particular, we will perform additional screening tests for platelet function disorders, because, to date, it is still very difficult to diagnose inherited PFDs in children, eg.
due to large amounts of blood required for analyses. The following tests will be performed for this specific subgroup of children only:
• Proteomic screen by mass spectrometry for PFDs
• Flow cytometry approaches to assess expression levels of critical platelet receptors such as glycoprotein (GP) Ib, GPV, GPIX and integrin alpha 2b bèta 3 (α IIb β 3 )
• Electron microscopy
• DNA isolation for genetic screening of rare PFDs
Blood sample collection
Blood samples will be collected and analyzed at the central laboratory of the participating center. The amount of blood taken will essentially be the same as usual for the diagnostic work-up in the hematology clinics. Results from the laboratory tests will be used as the reference standard. Based on these results, patients will be classified according to the presence or absence of an inherited bleeding disorder such as vWD, hemophilia or PFD. The "in-house" laboratory norm will be used to define the normal ranges of laboratory parameters. The diagram in Figure 1 provides an overview of the standard diagnostic and study specific procedures for eligible patients. 
Platelet function disorders
PFDs can be classified into inherited and acquired disorders. Inherited disorders can be further classified into adhesion, activation, secretion and aggregation defects. Acquired 
Classification of factor levels for coagulation factor disorders (tested at least twice)
Statistical analysis
The primary aim of the study is to evaluate the diagnostic accuracy of the iCHEC BAT. In addition, the influence of age, sex and type of bleeding disorder on the total bleeding score and the score of individual bleeding items will be analyzed.
We will analyze differences between affected (children diagnosed with an inherited bleeding disorder) and unaffected children (not diagnosed with an inherited bleeding disorder). Patients are classified as affected or unaffected based on the results of the diagnostic laboratory work-up, as described above. Affected and unaffected children will be compared with respect to:
• Total cumulative bleeding score 
Safety reporting
Adverse events are defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational product / trial procedure/ the experimental intervention. All adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded.
The iCHEC study consists of a questionnaire and a blood draw. In current practice, patients and/or caregivers also fill in a bleeding questionnaire (ISTH-BAT or PBQ) for diagnostic purposes. The iCHEC BAT contains questions that are of similar intention and will therefore not be more burdening to the patient. A blood draw is also part of the current diagnostic work-up for hemorrhagic disorders. Thus, this study will not change the standard diagnostic procedures. We do not expect that drawing an extra amount of (max 5 ml) blood in a selected group of patients in Dutch centers will lead to an increased risk for the patient.
Study status
The first patient was enrolled on March 28 th ,2017. Data collection is expected to take approximately one year. Results will be presented at scientific meetings and published in peer-reviewed journals. All publications and presentations related to the study will be authorized and reviewed by the study investigators.
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This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Coagulation disorders) BAT) to improve on these characteristics. We aim to evaluate the diagnostic accuracy of the iCHEC BAT as a screening tool for children who are suspected for having a bleeding disorder.
Methods and analysis
This is a prospective cohort study. Children (age 0-18 years) suspected for a bleeding disorder who present at tertiary hematology clinics, and/or their parents/guardians, will be asked to complete the iCHEC BAT. Sensitivity was increased by inclusion of pediatricspecific bleeding symptoms and novel qualitative questions per bleeding symptom. Efficiency was improved by developing a self-administered (online) version of the questionnaire.
Flexibility for changes in the bleeding phenotype of developing children was improved by including questions that define when the bleeding symptoms occurred in the past. The diagnostic accuracy of the specific bleeding items will be evaluated by receiver operator characteristic curves, using classification based on the results from laboratory assessment as the reference standard.Analysis of the discriminative power of individual bleeding symptoms will be assessed.
Ethics and dissemination
The study has been approved by medical ethics committees of all participating centers in the Netherlands, Canada and the United Kingdom. All pediatric subjects and/or their parents/guardians will provide written informed consent. Study results will be submitted for publication in peer-reviewed journals. 
STRENGTHS AND LIMITATIONS OF THE STUDY
• Strength: The iCHEC BAT is designed to pick up subtle cues in the bleeding history of a child, thereby improving the measurement properties of BATs for use in children.
• Limitation: The results of this study are not generalizable to primary and secondary care due to a different spectrum of prevalence of inherited bleeding disorders compared to tertiary hematology centers; additional studies will be required to determine diagnostic performance of the iCHEC BAT in these settings. It has been shown that high bleeding scores are associated with the presence of an inherited bleeding disorder 4 . However, none of the existing questionnaires/scores were designed with the evaluation of pediatric symptoms being the primary aim. The PBQ and ISTH-BAT are not sensitive enough to pick up subtle cues in the bleeding history of a child because not all the information that is collected about the bleeding is used for calculating the bleeding score and this may lead to underestimation of bleeding symptoms. Also, the PBQ and ISTH-BAT are inflexible with respect to changes in the bleeding phenotype of rapidly developing children. Finally, a self-administered BAT would help to optimize the efficiency of bleeding history assessment. Thus, optimization of this screening tool is necessary.
Therefore, we have developed a novel BAT: the iCHEC BAT. For construction of the iCHEC BAT, the PBQ and ISTH-BAT were used as templates. From a thorough literature review and consultation with experts, we have identified additional pediatric-specific bleeding symptoms and qualitative questions per bleeding symptom. These items and questions were added to the iCHEC BAT to increase its sensitivity for detection of subtle cues in the bleeding history. The PBQ and ISTH-BAT calculate a bleeding score based on information about the is not used for diagnostic purposes. In contrast to the scoring systems of the PBQ and ISTH-BAT, the iCHEC BAT scoring system will use all the information that has been collected from the completed questionnaire for calculating a bleeding score. For example, the iCHEC BAT includes ánd scores more detailed information about epistaxis, whereas the PBQ and ISTH-BAT only score information about the presence (no/trivial) and the treatment of the most severe epistaxis episode for calculating the bleeding score. We hypothesize that including more detailed information about a bleeding symptom may contribute to a better measurement of the bleeding tendency of a child. The sensitivity, specificity, positive predictive value and negative predictive value of the PBQ for diagnosing VWD are 83%, 79%, 0.14, and 0.99, respectively. Although the 95% confidence intervals (CIs) for specificity are reasonable (72-86%), they are quite wide for sensitivity (42-124%), because of the small number of true positives The main goal of this study is to evaluate the diagnostic accuracy of the iCHEC BAT, using results from laboratory screening tests as reference (gold standard). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS
Study design
Inclusion criteria
Exclusion criteria
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Sample size calculation
The prevalence of an inherited bleeding disorder in children presenting with bleeding symptoms at a tertiary clinic is approximately 20-25% 6, 7, 8 . Assuming a sensitivity of 90% and specificity of 70%, a sample size of 200 children, of which about 45 will be affected, will yield 95% confidence intervals (CI) of 76-96% and 64-78% for sensitivity and specificity, respectively, which we consider sufficiently narrow.
Recruitment and consent
Recruitment and consent procedures of patients at participating centers in the Netherlands will be as follows: after referral and scheduling the appointment for evaluation of bleeding symptoms at the participating tertiary hematology clinic, subjects will be informed by email or by letter about this study. The secured link to the online version of the iCHEC BAT will be sent by email to the study participants. Patients and/or caregivers will fill in the questionnaire prior to the doctor's appointment. Informed consent will be signed by one of investigators or the treating physician when the patient visits the hospital with both parents/guardians of the patient and the patient, when 12 years or older.
Outcomes
Data collection
Patient characteristics
The following patient data will be collected: month and year of birth to calculate age; body weight and height to calculate BMI; family history; medical history; and use of medication. An online version of the iCHEC BAT is available for patients included in the Netherlands.
Patients and/or their parents/guardians fill in the questionnaire at a computer before they visit the doctor in the hospital. For patients included outside the Netherlands, a paper version of the questionnaire is available. These patients and/or parents/guardians fill in the questionnaire in the waiting room before they visit the doctor. The questions that are necessary to calculate the PBQ and ISTH-BAT bleeding scores are incorporated in the iCHEC BAT. Bleeding scores will be calculated, including the total summative bleeding score, scores per bleeding item and scores of individual questions per bleeding item.
Diagnostic work-up
• Fibrinogen 
Additional laboratory tests
In participating centers in the Netherlands, we will collect extra blood for additional platelet tests in a subgroup of patients. This subgroup includes subjects with a high iCHEC bleeding score, who were not diagnosed with a bleeding disorder on the basis of routine diagnostic laboratory tests. In particular, we will perform additional screening tests for platelet function disorders, because, to date, it is still very difficult to diagnose inherited platelet function disorders (PFDs) in children, eg. due to large amounts of blood required for analyses. The following tests will be performed for this specific subgroup of children only:
• Proteomic screen by mass spectrometry for PFDs • Electron microscopy
Blood sample collection
Blood samples will be collected and analyzed at the central laboratory of the participating center. The amount of blood taken will essentially be the same as usual for the diagnostic work-up in the hematology clinics.
Results from the laboratory tests will be used as the reference standard. Based on these results, patients will be classified according to the presence or absence of an inherited bleeding disorder such as vWD, hemophilia or PFD. The "in-house" laboratory norm will be used to define the normal ranges of laboratory parameters. The diagram in Figure 1 provides an overview of the standard diagnostic and study specific procedures for eligible patients.
Disease definitions
von Willebrand disease 
Statistical analysis
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Ethical considerations
Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study for urgent medical reasons.
The Medical Ethics Committee of the Academic Medical Center in Amsterdam, The
Netherlands has approved this study (with registration number: NL56790.018.16). All other participating centers have obtained local ethical approval for the study. All participants provide written informed consent.
Safety reporting
Study status
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K.F. conceived the work and designed the study protocol, initially drafted, revised and accepted the version to be published, supervises data acquisition, agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Figure 1 . Overview of the standard diagnostic (in black) and study specific procedures (in red). PBQ, Pediatric Bleeding Questionnaire; ISTH-BAT, International Society on Thrombosis and Haemostasis Bleeding Assessment Tool; APTT, activated partial thromboplastin time; PTT, partial thromboplastin time; PFA, platelet function analyzer; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FXI, factor XI; FXIII, factor XIII; vWF, von Willebrand factor; Ag, antigen; Act, activity; FACS, Fluorescence Activated Cell Sorting; MS, mass spectrometry; EM, electron microscopy 123x208mm (300 x 300 DPI) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
